BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

Impact · against what's priced in

BioMarin's stock is likely to see a positive catalyst following the successful Phase 3 trial of VOXZOGO for hypochondroplasia. The statistically significant growth velocity improvement of 2.33 cm/yr and the lack of new safety signals provide a clear path toward a Q3 2026 sNDA submission, expanding the drug's addressable market.

BMRN+0.70

No priced-in read yet